This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Augmedix Past Earnings Performance

Past criteria checks 0/6

Augmedix's earnings have been declining at an average annual rate of -7.1%, while the Healthcare Services industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 33.8% per year.

Key information

-7.1%

Earnings growth rate

92.7%

EPS growth rate

Healthcare Services Industry Growth1.7%
Revenue growth rate33.8%
Return on equity-227.7%
Net Margin-46.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jun 19
Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

May 21
Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Apr 25
Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Mar 24

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 09
Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Augmedix reports Q2 results

Aug 08

Augmedix: A Splendid Long-Term Investing Opportunity

Jan 21

Revenue & Expenses Breakdown

How Augmedix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:AUGX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2452-243514
31 Mar 2449-203112
31 Dec 2345-192911
30 Sep 2341-202811
30 Jun 2337-212711
31 Mar 2334-242711
31 Dec 2231-242610
30 Sep 2229-24259
30 Jun 2227-21249
31 Mar 2224-19228
31 Dec 2122-17217
30 Sep 2120-16206
30 Jun 2119-17195
31 Mar 2117-16174
31 Dec 2016-16165
30 Sep 2016-15155
30 Jun 2015-18146
31 Mar 2015-19157
31 Dec 1914-18147
31 Dec 1811-24177

Quality Earnings: AUGX is currently unprofitable.

Growing Profit Margin: AUGX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AUGX is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare AUGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUGX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.9%).


Return on Equity

High ROE: AUGX has a negative Return on Equity (-227.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/03 14:47
End of Day Share Price 2024/10/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Augmedix, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William SutherlandBenchmark Company
Yuan ZhiB. Riley Securities, Inc.
Elizabeth AndersonEvercore ISI